Jinyu Bio-Technology Co Financial Leverage
The Financial Leverage (Equity Multiplier) of Jinyu Bio-Technology Co (600201.SS) as of Sep 11, 2026 is 1.27. In the previous year, Financial Leverage (Equity Multiplier) was 1.28 — a change of -0.60% (lower).
Get this data via API
Financial Data API
Financial Leverage
1.27
YoY
-0.60%
Last updated:
The Jinyu Bio-Technology Co Financial Leverage history
3 Years
10 Years
25 Years
Max
| YEAR | Financial Leverage | YoY |
|---|---|---|
| 1.27 | -0.60% | |
| 1.28 | +1.66% | |
| 1.26 | +0.57% | |
| 1.25 | -0.61% | |
| 1.26 | +4.85% | |
| 1.20 | -4.21% | |
| 1.25 | -1.30% | |
| 1.27 | +9.64% | |
| 1.16 | -5.93% | |
| 1.23 | -4.07% | |
| 1.28 | — |
Jinyu Bio-Technology Co Stock analysis
Frequently Asked Questions about Jinyu Bio-Technology Co stock
Financial Leverage (Equity Multiplier) of Jinyu Bio-Technology Co is 1.27 in 2026.
Financial Leverage (Equity Multiplier) of Jinyu Bio-Technology Co changed from 1.28 to 1.27, representing a -0.60% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Jinyu Bio-Technology Co with sector peers and the industry average to assess whether it is attractive.
Leverage — Jinyu Bio-Technology Co
All Key Metrics — Jinyu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth